idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
The research team led by Prof. Frank Buchholz at the Carl Gustav Carus Medical Faculty of the Technical University of Dresden has succeeded in developing an enzyme that can efficiently and specifically correct a gene mutation in the Factor VIII gene, which is responsible for a severe form of hemophilia A.
People suffering from the severe form of hemophilia A are unable to produce a certain protein necessary for blood clotting. As a consequence, Hemophilia A patients often suffer from spontaneous bleeding, which can lead to chronic painful and degenerative joint disease, hematomas and also potentially life-threatening internal bleeding. Currently, patients are treated with a protein replacement therapy using recombinant factor VIII, which typically must be administered intravenously several times a week. Patients benefit from this treatment. However, so far this therapy can only alleviate the symptoms of the disease, but not cure the patients.
This fact might change in the future due to the designer-recombinase RecF8 generated by the RecTech team around Prof. Frank Buchholz. RecF8 is the newest innovation based on the designer-recombinase platform technology developed by the research group. Designer-recombinases represent a versatile and flexible genome editing tool that allows for precise and efficient genome modifications. The now presented RecF8 designer-recombinase can for the first time correct the defective factor VIII gene with high precision. About 50% of severe hemophilia A cases are caused by a so-called gene inversion - a gene segment that is practically turned the wrong way around. RecF8 is able to detect specific sequences in this inversion and rotate correctly the inverted DNA section back into the right direction. The team was able to show that the gene inversion causing hemophilia A could be reversed after treatment with RecF8 in patient cells, thus curing the cells. These results again demonstrate the high therapeutic potential of designer recombinases, as they could now also be used to correct disease-causing gene inversions.
"The next step is of course to prove the safety of RecF8 in animal models. Should the efficiency as well as specificity also be demonstrated in the animal model, a clinical trial with patients could follow. The results so far are promising and show the high potential of the technology for future clinical application," explains Prof. Buchholz.
References:
Correction of a Factor VIII genomic inversion with designer-recombinases
Lansing F, Mukhametzyanova L, Rojo-Romanos T, Iwasawa K, Kimura M, Paszkowski-Rogacz M, Karpinski J, Grass T, Sonntag J, Schneider PM, Günes C, Hoersten J, Schmitt LT, Rodriguez-Muela N, Knöfler R, Takebe T & Buchholz F. Nature Communications volume 13, Article number: 422 (2022)
Pairing of single mutations yields obligate Cre-type site-specific recombinases.
Hoersten J, Ruiz-Gómez G, Lansing F, Rojo-Romanos T, Schmitt LT, Sonntag J, Pisabarro MT, Buchholz F. Nucleic Acids Res. 2021 Dec 24:gkab1240. doi: 10.1093/nar/gkab1240. Online ahead of print. PMID: 34951450
RecTech: RecTech is a project funded by the German Federal Ministry of Education and Research (BMBF) within the GO-Bio Innitiative. Within the planned spin-off RecTech, the research results mentioned here are to be further developed and commercialized.
Note on the use of image material: The use is free of charge. The TU Dresden grants permission for one-time use in connection with reporting on the subject of the press release. Please indicate as picture credits: ©TU Dresden, Buchholz Lab. The image material may only be passed on to third parties after prior consultation with the TUD press office (Tel. +49-351-463-32398, e-mail: pressestelle@tu-dresden.de). Use for commercial purposes is prohibited.
Dr. Felix Lansing
Medizinische Fakultät Carl Gustav Carus der Technischen Universität Dresden
Tel.: +49 (0) 351 463-40091
E-Mail: felix.lansing@tu-dresden.de
Prof. Frank Buchholz
Medizinische Fakultät Carl Gustav Carus der Technischen Universität Dresden
Tel.: +49 (0) 351 463-40288
E-Mail: frank.buchholz@tu-dresden.de
Schematic representation of the correction of gene inversion in the F8 gene with the designer recomb ...
©TU Dresden, Buchholz Lab
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
